Login
KAMADA LTD logo

KAMADA LTD

kamada.com

What Do They Do?

Sells specialty plasma-derived medicines for rare and serious conditions to wholesalers, distributors and healthcare providers, and distributes licensed medicines in Israel.

How Do They Make Money?

Kamada sells products to strategic partners and distributors, with sales tied to delivery. It also earns royalties when licensees sell products using its know-how and patents.

FY2025 revenue

Who Are Their Customers?

In the U.S., wholesalers and local distributors buy several medicines directly; elsewhere, strategic partners and local distributors handle sales of proprietary products. Israeli health plans and hospitals buy products directly or through a logistics partner.

How Are They Changing?

Growing. Revenue grew 74% in 4 years, from $103.6M in FY2021 to $180.5M in FY2025, about 15% a year.

Biosimilar distribution The Israeli distribution business has moved from preparing a biosimilar portfolio for future launch to selling biosimilar medicines.

Who Do They Compete With?

Competes with CSL Behring, Grifols, Kedrion, ADMA, Sanofi Pasteur, BPL, Takeda, LFB, Sanofi, Beam Therapeutics, Wave Therapeutics, AlveoGene, Regeneron/Tessera Thrapeutics, Biotest, Merck, Roche, Pfizer, Gilead Sciences, and Octapharma

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support